Crohn's Disease Forum » Parents of Kids with IBD » Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

02-20-2018, 01:33 PM   #1
Forum Monitor
Maya142's Avatar
Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

New study confirming that TNF inhibitors do not increase cancer risk in kids.

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk
By Jack Cush, MD | 20 February 2018

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

While it is well known that TNFi do not confer any higher or additional risk of neoplasia in adults treated for rheumatoid arthritis and other inflammatory conditions, the issue is less clear in children. Current product labeling states "..lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers..", based on the best available data (albeit limited) from registries and spontaneous postmarketing reports.

What has been lacking is clear understanding of the background cancer risk in polyarticular JIA along with well-designed trials to examine if there is an additional risk imposed by the biologic drug.

This retrospective cohort study examined pediatric patients with juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO), exposed to their first TNFi. Standardised incidence ratios (SIRs) comparing the observed number of malignancies to the expected numbers according to cancer surveillance data.

Among 15,598 children treated with TNFi and 73 839 children without TNFi exposure, they found 15 malignancies among children with TNFi use (SIR 2.9 (1.6 to 4.9)) and 42 malignancies among children without TNFi use (SIR 2.1 (1.5 to 2.9)).

The adjusted hazard ratio (aHR) was 1.58 (0.88 to 2.85) for TNFi use versus no TNFi use.

In pIBD, thiopurine plus TNFi use was associated with a higher SIR (aHR 6.0 (1.2 to 17.5)) compared with TNFi use without thiopurine use (2.5 (0.7 to 6.4)).

Children diagnosed with JIA, pIBD and pPsO had an increased rate of malignancy compared with the general population.

However, TNFi did not appear to significantly further increase the risk compared with no TNFi use.
Mom of M (20)
diagnosed with Crohn's Disease at 16
Juvenile Idiopathic Arthritis at 12
Juvenile Ankylosing Spondylitis at 16

Mom of S (23)
dx with JIA at 14
Ankylosing Spondylitis at 18
02-20-2018, 05:44 PM   #2
Jelly loves Peanut butter
Join Date: Nov 2016
Location: Southern California

My Support Groups:
Thank you for posting that!

Mom of Lincoln (age 11)

Dx. Crohn's 9/2016 (age 9)
Dx. Juvenile Spondyloarthritis 9/2017 (age 10)

6-Mp 9/2016-10/2017
Remicade started 9/2017
MTX started 9/2017
02-20-2018, 09:55 PM   #3
Lynda Lynda
Join Date: Feb 2018
Location: Glendale, Arizona

My Support Groups:
Thank you for sharing.
02-21-2018, 12:20 AM   #4
Forum Monitor
Mehita's Avatar
Join Date: Nov 2011
Location: Minnesota

My Support Groups:
DS saw his GI today and he was telling us about this. Great news!
Mom of DS, age 17, dx Crohn's and Celiac Oct 2008
- Remicade, started Nov 2013
- added Methotrexate/Folate March 2016
- Multivitamins, Probiotics, Vit D
- Small bowel resection, Jan 2013
02-21-2018, 10:33 PM   #5
Senior Member
Pilgrim's Avatar
Join Date: Jul 2014
Location: Ontario

My Support Groups:
Time to get my son some TNFi !

Crohn's Disease Forum » Parents of Kids with IBD » Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk
Thread Tools

All times are GMT -5. The time now is 05:27 PM.
Copyright 2006-2017